Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. The DELFT (Drug Eluting stent for LeFT main) Registry

Emanuele Meliga, Hector Manuel Garcia-Garcia, Marco Valgimigli, Alaide Chieffo, Giuseppe Biondi-Zoccai, Andrew O. Maree, Stephen Cook, Lindsay Reardon, Claudio Moretti, Stefano De Servi, Igor F. Palacios, Stephen Windecker, Antonio Colombo, Ron van Domburg, Imad Sheiban, Patrick W. Serruys

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to investigate the long-term safety and efficacy of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease. Background: Long-term clinical outcomes after DES implantation for ULMCA disease have not yet been ascertained. Methods: From April 2002 to April 2004, 358 consecutive patients who underwent PCI with DES implantation for de novo lesions on ULMCA were retrospectively selected and analyzed in 7 European and U.S. tertiary care centers. No patients were excluded from the analysis, and all patients had a minimum follow-up of 3 years. Results: Technical success rate was 100%. Procedural success rate was 89.6%. After 3 years, major adverse cardiovascular events (MACE)-free survival in the whole population was 73.5%. According to the Academic Research Consortium definitions, cardiac death occurred in 9.2% of patients, and reinfarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) occurred in 8.6%, 5.8%, and 14.2% of patients, respectively. Definite stent thrombosis occurred in 2 patients (specifically at 0 and 439 days). In elective patients, the 3-year MACE-free survival was 74.2%, with mortality, reinfarction, TLR, and TVR rates of 6.2%, 8.3%, 6.6%, and 16%, respectively. In the emergent group the 3-year MACE-free survival was 68.2%, with mortality, reinfarction, TLR, and TVR rates of 21.4%, 10%, 2.8%, and 7.1%, respectively. Conclusions: Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.

Original languageEnglish
Pages (from-to)2212-2219
Number of pages8
JournalJournal of the American College of Cardiology
Volume51
Issue number23
DOIs
Publication statusPublished - Jun 10 2008

Fingerprint

Drug-Eluting Stents
Registries
Coronary Artery Disease
Disease-Free Survival
Percutaneous Coronary Intervention
Mortality
Tertiary Care Centers
Stents
Coronary Vessels
Thrombosis
Safety
Research
Population

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. The DELFT (Drug Eluting stent for LeFT main) Registry. / Meliga, Emanuele; Garcia-Garcia, Hector Manuel; Valgimigli, Marco; Chieffo, Alaide; Biondi-Zoccai, Giuseppe; Maree, Andrew O.; Cook, Stephen; Reardon, Lindsay; Moretti, Claudio; De Servi, Stefano; Palacios, Igor F.; Windecker, Stephen; Colombo, Antonio; van Domburg, Ron; Sheiban, Imad; Serruys, Patrick W.

In: Journal of the American College of Cardiology, Vol. 51, No. 23, 10.06.2008, p. 2212-2219.

Research output: Contribution to journalArticle

Meliga, E, Garcia-Garcia, HM, Valgimigli, M, Chieffo, A, Biondi-Zoccai, G, Maree, AO, Cook, S, Reardon, L, Moretti, C, De Servi, S, Palacios, IF, Windecker, S, Colombo, A, van Domburg, R, Sheiban, I & Serruys, PW 2008, 'Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. The DELFT (Drug Eluting stent for LeFT main) Registry', Journal of the American College of Cardiology, vol. 51, no. 23, pp. 2212-2219. https://doi.org/10.1016/j.jacc.2008.03.020
Meliga, Emanuele ; Garcia-Garcia, Hector Manuel ; Valgimigli, Marco ; Chieffo, Alaide ; Biondi-Zoccai, Giuseppe ; Maree, Andrew O. ; Cook, Stephen ; Reardon, Lindsay ; Moretti, Claudio ; De Servi, Stefano ; Palacios, Igor F. ; Windecker, Stephen ; Colombo, Antonio ; van Domburg, Ron ; Sheiban, Imad ; Serruys, Patrick W. / Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. The DELFT (Drug Eluting stent for LeFT main) Registry. In: Journal of the American College of Cardiology. 2008 ; Vol. 51, No. 23. pp. 2212-2219.
@article{eeea696771c14c4bb8ee2d58cb1dcef9,
title = "Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. The DELFT (Drug Eluting stent for LeFT main) Registry",
abstract = "Objectives: The purpose of this study was to investigate the long-term safety and efficacy of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease. Background: Long-term clinical outcomes after DES implantation for ULMCA disease have not yet been ascertained. Methods: From April 2002 to April 2004, 358 consecutive patients who underwent PCI with DES implantation for de novo lesions on ULMCA were retrospectively selected and analyzed in 7 European and U.S. tertiary care centers. No patients were excluded from the analysis, and all patients had a minimum follow-up of 3 years. Results: Technical success rate was 100{\%}. Procedural success rate was 89.6{\%}. After 3 years, major adverse cardiovascular events (MACE)-free survival in the whole population was 73.5{\%}. According to the Academic Research Consortium definitions, cardiac death occurred in 9.2{\%} of patients, and reinfarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) occurred in 8.6{\%}, 5.8{\%}, and 14.2{\%} of patients, respectively. Definite stent thrombosis occurred in 2 patients (specifically at 0 and 439 days). In elective patients, the 3-year MACE-free survival was 74.2{\%}, with mortality, reinfarction, TLR, and TVR rates of 6.2{\%}, 8.3{\%}, 6.6{\%}, and 16{\%}, respectively. In the emergent group the 3-year MACE-free survival was 68.2{\%}, with mortality, reinfarction, TLR, and TVR rates of 21.4{\%}, 10{\%}, 2.8{\%}, and 7.1{\%}, respectively. Conclusions: Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.",
author = "Emanuele Meliga and Garcia-Garcia, {Hector Manuel} and Marco Valgimigli and Alaide Chieffo and Giuseppe Biondi-Zoccai and Maree, {Andrew O.} and Stephen Cook and Lindsay Reardon and Claudio Moretti and {De Servi}, Stefano and Palacios, {Igor F.} and Stephen Windecker and Antonio Colombo and {van Domburg}, Ron and Imad Sheiban and Serruys, {Patrick W.}",
year = "2008",
month = "6",
day = "10",
doi = "10.1016/j.jacc.2008.03.020",
language = "English",
volume = "51",
pages = "2212--2219",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "23",

}

TY - JOUR

T1 - Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. The DELFT (Drug Eluting stent for LeFT main) Registry

AU - Meliga, Emanuele

AU - Garcia-Garcia, Hector Manuel

AU - Valgimigli, Marco

AU - Chieffo, Alaide

AU - Biondi-Zoccai, Giuseppe

AU - Maree, Andrew O.

AU - Cook, Stephen

AU - Reardon, Lindsay

AU - Moretti, Claudio

AU - De Servi, Stefano

AU - Palacios, Igor F.

AU - Windecker, Stephen

AU - Colombo, Antonio

AU - van Domburg, Ron

AU - Sheiban, Imad

AU - Serruys, Patrick W.

PY - 2008/6/10

Y1 - 2008/6/10

N2 - Objectives: The purpose of this study was to investigate the long-term safety and efficacy of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease. Background: Long-term clinical outcomes after DES implantation for ULMCA disease have not yet been ascertained. Methods: From April 2002 to April 2004, 358 consecutive patients who underwent PCI with DES implantation for de novo lesions on ULMCA were retrospectively selected and analyzed in 7 European and U.S. tertiary care centers. No patients were excluded from the analysis, and all patients had a minimum follow-up of 3 years. Results: Technical success rate was 100%. Procedural success rate was 89.6%. After 3 years, major adverse cardiovascular events (MACE)-free survival in the whole population was 73.5%. According to the Academic Research Consortium definitions, cardiac death occurred in 9.2% of patients, and reinfarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) occurred in 8.6%, 5.8%, and 14.2% of patients, respectively. Definite stent thrombosis occurred in 2 patients (specifically at 0 and 439 days). In elective patients, the 3-year MACE-free survival was 74.2%, with mortality, reinfarction, TLR, and TVR rates of 6.2%, 8.3%, 6.6%, and 16%, respectively. In the emergent group the 3-year MACE-free survival was 68.2%, with mortality, reinfarction, TLR, and TVR rates of 21.4%, 10%, 2.8%, and 7.1%, respectively. Conclusions: Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.

AB - Objectives: The purpose of this study was to investigate the long-term safety and efficacy of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for unprotected left main coronary artery (ULMCA) disease. Background: Long-term clinical outcomes after DES implantation for ULMCA disease have not yet been ascertained. Methods: From April 2002 to April 2004, 358 consecutive patients who underwent PCI with DES implantation for de novo lesions on ULMCA were retrospectively selected and analyzed in 7 European and U.S. tertiary care centers. No patients were excluded from the analysis, and all patients had a minimum follow-up of 3 years. Results: Technical success rate was 100%. Procedural success rate was 89.6%. After 3 years, major adverse cardiovascular events (MACE)-free survival in the whole population was 73.5%. According to the Academic Research Consortium definitions, cardiac death occurred in 9.2% of patients, and reinfarction, target lesion revascularization (TLR), and target vessel revascularization (TVR) occurred in 8.6%, 5.8%, and 14.2% of patients, respectively. Definite stent thrombosis occurred in 2 patients (specifically at 0 and 439 days). In elective patients, the 3-year MACE-free survival was 74.2%, with mortality, reinfarction, TLR, and TVR rates of 6.2%, 8.3%, 6.6%, and 16%, respectively. In the emergent group the 3-year MACE-free survival was 68.2%, with mortality, reinfarction, TLR, and TVR rates of 21.4%, 10%, 2.8%, and 7.1%, respectively. Conclusions: Routine DES implantation in ULMCA disease seems encouraging, with favorable long-term clinical results.

UR - http://www.scopus.com/inward/record.url?scp=44449165460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449165460&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2008.03.020

DO - 10.1016/j.jacc.2008.03.020

M3 - Article

C2 - 18534266

AN - SCOPUS:44449165460

VL - 51

SP - 2212

EP - 2219

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 23

ER -